D P Yee1, D Menzies, P Brassard. 1. Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill University Health Center, Montreal, Quebec, Canada.
Abstract
BACKGROUND: In Quebec, 6.2% of all tuberculosis (TB) isolates from Canadian-born patients are resistant to pyrazinamide (PZA) alone. The clinical significance of PZA-monoresistant (PZA(MR)) TB is unknown. METHODS: Canadian-born patients with PZA(MR) TB diagnosed between 1 January 1990 and 31 December 2000 and reported in a prior study were compared to randomly selected Canadian-born patients with fully susceptible isolates diagnosed within the same time period. RESULTS: A total of 318 patients were eligible, of whom 40 (12.6%) had missing outcome information. Mean total duration of treatment was respectively 9.0 and 8.9 months for those with PZA(MR) and pan-susceptible strains. Respectively 91% and 89% of PZA(MR) and pan-susceptible patients received at least 6 months of rifampin-containing treatment. Among 67 patients with PZA(MR) TB, 51 (76%) were cured, 3 (4%) relapsed, none failed treatment, and 16 (24%) died within 6 months of diagnosis. Of 211 subjects with fully susceptible isolates, 181 (86%) were cured, 2 (1%) relapsed, 2 (1%) failed treatment, and 30 (14%) died within 6 months of diagnosis. PZA monoresistance was associated with decreased odds of successful clinical outcomes compared with pan-susceptible TB (OR 0.4, 95%CI 0.2-0.8). CONCLUSION: Patients with PZA(MR) TB had significantly worse clinical outcomes than patients with fully susceptible strains.
BACKGROUND: In Quebec, 6.2% of all tuberculosis (TB) isolates from Canadian-born patients are resistant to pyrazinamide (PZA) alone. The clinical significance of PZA-monoresistant (PZA(MR)) TB is unknown. METHODS: Canadian-born patients with PZA(MR) TB diagnosed between 1 January 1990 and 31 December 2000 and reported in a prior study were compared to randomly selected Canadian-born patients with fully susceptible isolates diagnosed within the same time period. RESULTS: A total of 318 patients were eligible, of whom 40 (12.6%) had missing outcome information. Mean total duration of treatment was respectively 9.0 and 8.9 months for those with PZA(MR) and pan-susceptible strains. Respectively 91% and 89% of PZA(MR) and pan-susceptible patients received at least 6 months of rifampin-containing treatment. Among 67 patients with PZA(MR) TB, 51 (76%) were cured, 3 (4%) relapsed, none failed treatment, and 16 (24%) died within 6 months of diagnosis. Of 211 subjects with fully susceptible isolates, 181 (86%) were cured, 2 (1%) relapsed, 2 (1%) failed treatment, and 30 (14%) died within 6 months of diagnosis. PZA monoresistance was associated with decreased odds of successful clinical outcomes compared with pan-susceptible TB (OR 0.4, 95%CI 0.2-0.8). CONCLUSION:Patients with PZA(MR) TB had significantly worse clinical outcomes than patients with fully susceptible strains.
Authors: Claudio U Köser; Silke Feuerriegel; David K Summers; John A C Archer; Stefan Niemann Journal: Antimicrob Agents Chemother Date: 2012-09-24 Impact factor: 5.191
Authors: Jonathan M Budzik; Leah G Jarlsberg; Julie Higashi; Jennifer Grinsdale; Phil C Hopewell; Midori Kato-Maeda; Payam Nahid Journal: PLoS One Date: 2014-04-23 Impact factor: 3.240
Authors: Sarah Sengstake; Indra L Bergval; Anja R Schuitema; Jessica L de Beer; Jody Phelan; Rina de Zwaan; Taane G Clark; Dick van Soolingen; Richard M Anthony Journal: BMC Infect Dis Date: 2017-07-12 Impact factor: 3.090
Authors: Vanessa Deggim-Messmer; Guido V Bloemberg; Claudia Ritter; Antje Voit; Rico Hömke; Peter M Keller; Erik C Böttger Journal: EBioMedicine Date: 2016-06-14 Impact factor: 8.143
Authors: Mariam O Fofana; Sourya Shrestha; Gwenan M Knight; Ted Cohen; Richard G White; Frank Cobelens; David W Dowdy Journal: Antimicrob Agents Chemother Date: 2017-02-23 Impact factor: 5.191